History

2020
Jun
  • $8M Series A funding has been done.
2019
Aug
  • A research paper on ONG41008`s anti-inflammatory & anti-fibrosis efficacy has been posted on BioRxiv journal.
Jul
  • A US patent of ONG41008 as an anti-fibrosis compound has been granted. (10,370,364)
Jan
  • A research paper on ONG21001`s anti-fibrosis & cell reversion efficacy on fibrotic cells has been published on EbioMedicine journal.
2018
Jun
  • A Korean patent of ONG41008 as an anti-fibrosis compound has been granted. (10-1871166)
2017
Aug
  • $1M Pre-series A funding has been done.
Feb
  • Obtained a certification of qualified venture company from Korea government.
2016
Dec
  • Established Korea government certified R&D center
Jul
  • Established a head office in Gasan-digital district, Seoul.
2015
Oct
  • A patent for osteoporosis treatment has been granted
    by KIPO (10-1564170)
May
  • A patent for osteoporosis treatment has been granted
    by KIPO (10-1522729)
Mar
  • A publication about osteoporosis treatment was
    highlighted by the ASBMB
2014
Aug
  • A patent for osteoporosis treatment has been granted
    by KIPO (10-1433794)
2013
Sep
  • Company founded